diagnosi
carv
rti
depend
specimen
laboratori
assay
avail
potenti
specimen
diagnost
test
includ
nasopharyng
aspir
nasopharyng
wash
swab
prefer
flock
nasal
sampl
tracheal
aspir
bronchoalveolar
lavag
bal
pool
bilater
nasopharyng
throat
swab
often
prefer
nasopharyng
aspir
nasopharyng
wash
upper
rti
urti
bal
prefer
tracheal
aspir
diagnosi
lrti
laboratori
test
includ
nucleic
acid
amplif
test
nat
use
gener
term
describ
molecular
genet
test
polymeras
chain
reaction
other
detect
viral
dna
rnadirect
antigen
detect
dad
use
gener
term
describ
direct
detect
antigen
specimen
use
specif
antibodi
differ
assay
format
direct
fluoresc
antigen
enzymelink
immunoassay
immun
chromatographi
etc
viru
isol
cell
cultur
vic
use
gener
term
describ
cell
cultur
isol
infecti
replic
virus
vic
perform
use
convent
andor
shell
vial
cell
cultur
techniqu
combin
dad
agent
identif
vic
higher
clinic
specif
diseas
requir
dedic
virolog
laboratori
less
sensit
nat
compar
long
turnaround
time
day
dad
good
clinic
specif
short
turnaround
time
hour
lower
sensit
compar
vic
nat
nat
often
prefer
higher
sensit
accept
turnaround
time
hour
addit
potenti
quantifi
viral
load
multiplex
infecti
agent
detect
genet
variant
molecularli
character
nosocomi
outbreak
special
laboratori
detect
carv
asymptomat
patient
increas
use
sensit
nat
outlin
elsewher
previous
therefor
import
distinguish
patient
carv
infect
carv
infecti
diseas
provid
case
definit
compar
one
propos
european
centr
diseas
prevent
control
influenza
viru
work
group
agre
adapt
carv
leukemia
hsct
patient
tabl
urti
defin
detect
carv
includ
larynx
eg
sampl
nose
pharynx
larynx
conjunctiva
sinus
urti
diseas
urtid
defin
detect
carv
upper
respiratori
tract
fluid
specimen
togeth
symptom
andor
sign
caus
excludedlrti
defin
detect
carv
larynx
eg
sampl
trachea
bronchu
bronchoalveolar
site
lrti
diseas
lrtid
defin
patholog
sputum
product
hypoxia
pulmonari
infiltr
togeth
identif
carv
respiratori
secret
preferenti
sampl
taken
site
involv
tabl
repiratori
syncyti
viru
rsv
fall
distinct
antigen
subgroup
b
infect
occur
yearround
peak
cold
season
increas
urtid
eg
sinus
rhiniti
laryng
young
children
lrtid
eg
bronchiol
pneumonia
neonat
rsv
rti
patient
hsct
andor
hematolog
diseas
follow
commun
activ
reflect
increas
risk
communityacquir
household
nosocomi
transmiss
past
standard
diagnost
assay
dad
vic
techniqu
replac
complement
nat
mani
center
rsv
infect
occur
pediatr
patient
acut
myeloid
leukemia
adult
patient
hematolog
malign
hsct
infect
first
day
myeloabl
allogen
hsct
associ
increas
risk
persist
air
flow
declin
year
transplant
progress
lrtid
observ
mean
rang
leukemia
hsct
patient
averag
mortal
rang
review
elsewher
risk
factor
lrtid
includ
infect
preengraft
lymphopenia
older
age
allogen
hsct
sever
immunodefici
due
rang
contribut
factor
tabl
although
risk
poor
clinic
outcom
progress
increas
overal
fall
absolut
lymphocyt
count
vari
threshold
lymphopenia
report
clinic
studi
rapid
diagnost
infect
control
measur
deferr
chemotherapi
andor
hsct
import
consider
corticosteroid
treatment
risk
factor
leukemia
patient
role
corticosteroid
controversi
sinc
improv
respiratori
function
seen
despit
increas
rsv
load
prolong
shed
current
limit
evid
effect
treatment
lack
potent
antivir
drug
suffici
power
random
control
clinic
trial
rct
howev
pool
publish
studi
suggest
treat
urtid
hsct
leukemia
risk
lrtid
treat
manifest
lrtid
ribavirin
intraven
immunoglobulin
ivig
improv
outcom
recogn
proper
metaanalys
possibl
result
therefor
interpret
caution
human
parainfluenza
viru
hpiv
speci
caus
mild
urtid
throughout
year
typespecif
season
increas
urtid
lrtid
laryngotrach
bronchiol
pneumonia
seen
infect
children
autumn
spring
diagnosi
hpiv
infect
larg
made
use
dad
vic
cover
increasingli
replac
nat
also
identifi
adult
pediatr
leukemia
hsct
patient
symptomat
hpiv
infect
report
rang
least
onethird
manifest
lrtid
among
pediatr
patient
hpiv
infect
deem
communityacquir
given
estim
incub
period
day
confid
interv
ci
high
rate
asymptomat
shed
outpati
nosocomi
outbreak
infrequ
indic
need
infect
control
strategi
hsct
recipi
urtid
lrtid
commonli
detect
type
children
well
leukemia
hsct
patient
follow
nonmyeloabl
condit
associ
hpiv
urti
day
transplant
urti
associ
signific
airflow
declin
patient
may
progress
lrtid
fatal
outcom
report
risk
factor
lrtid
higher
corticosteroid
exposur
neutropenia
lymphopenia
infect
earli
allogen
hsct
higher
apach
ii
score
coinfect
treatment
option
limit
lack
effect
agent
rct
although
center
consid
treat
hpiv
urtid
patient
risk
factor
lrtid
hpiv
lrtid
ribavirin
andor
ivig
bronchiol
obliteran
syndrom
obstruct
airflow
declin
associ
hpiv
infect
within
first
month
allogen
hsct
persist
year
transplant
human
metapneumoviru
hmpv
paramyxoviru
close
relat
rsv
caus
increas
urtid
tracheobronch
children
adult
winter
hmpv
infect
commonli
diagnos
nat
rate
rang
first
year
allogen
hsct
asymptomat
prolong
shed
report
hsct
patient
hpmv
urtid
hsct
patient
present
flulik
symptom
hsct
patient
pneumonia
hmpv
frequent
codetect
pathogen
includ
bacteria
fungi
carv
well
cytomegaloviru
obscur
attribut
morbid
recipi
cytomegaloviru
seroposit
risk
factor
one
studi
hsct
patient
singl
case
sever
diseas
fatal
outcom
report
gener
recommend
treatment
current
made
although
center
consid
treat
hmpv
lrtid
ribavirin
andor
ivig
despit
lack
support
studi
human
coronavirus
hcov
circul
throughout
year
slight
predomin
winter
presum
caus
case
common
cold
hcov
divid
group
group
agent
molecularli
distinct
although
vic
dad
avail
center
use
nat
multiplex
format
report
rate
among
acut
symptomat
patient
incub
period
estim
day
ci
follow
median
detect
week
urtid
rhiniti
pharyng
laryng
common
manifest
case
lrtid
bronchiti
bronchiol
pneumonia
report
young
age
year
andor
immunodefici
patient
hsct
patient
hcov
detect
asymptomat
shed
may
high
symptomat
hsct
patient
coinfect
pathogen
frequent
lrtid
pneumonia
fatal
outcom
occur
rare
gener
recommend
treatment
limit
view
larg
benign
cours
lack
effect
antivir
agent
appropri
clinic
studi
human
rhinovirus
hrhv
belong
picornavirida
famili
divid
speci
call
b
c
encompass
serotyp
hrhv
circul
throughout
year
common
caus
urtid
rhinorrhea
postnas
drip
cough
occasion
tracheo
bronchiti
incub
period
estim
day
ci
diagnosi
larg
depend
nat
although
dad
rapid
test
vic
perform
special
laboratori
allogen
hsct
recipi
hrhv
identifi
frequent
carv
reach
cumul
incid
high
day
detect
rate
among
symptomat
hsct
patient
hrhv
infect
may
asymptomat
hsct
patient
prolong
shed
week
frequent
coinfect
carv
occur
patient
one
studi
report
higher
hrhv
load
correl
symptomat
present
lrtid
frank
pneumonia
rare
may
occur
allogen
hsct
infect
hrhv
usual
myeloabl
condit
estim
mortal
role
hrhv
treatment
limit
lack
agent
clinic
trial
human
enterovirus
henv
encompass
least
serotyp
also
belong
picornavirida
famili
henv
detect
hematolog
patient
urtid
may
progress
lrtid
although
henv
identifi
vic
current
laboratori
diagnosi
reli
mostli
nat
may
also
design
detect
picornavirus
hrhv
parechovirus
lymphopenia
risk
factor
lrtid
hsct
patient
human
bocaviru
hbov
human
polyomaviru
hpyv
infect
detect
patient
hematolog
malign
hsct
howev
studi
case
welldocu
clinic
cours
proven
diseas
histopatholog
miss
accordingli
risk
factor
diseas
need
therapi
well
defin
hbov
belong
parvovirida
famili
detect
children
rti
hbov
frequent
codetect
viral
agent
prevent
unequivoc
attribut
urtid
lrtid
bal
adult
patient
hbov
detect
case
recent
studi
suggest
hbov
load
copiesml
respiratori
fluid
like
indic
clinic
signific
replic
dissemin
hbov
infect
report
clinic
interpret
nat
signal
even
found
blood
organ
site
may
difficult
sinc
prolong
persist
describ
akin
parvoviru
hpyv
rti
includ
kipyv
wupyv
detect
children
acut
urtid
respect
kipyv
detect
frequent
respiratori
fluid
hsct
patient
compar
patient
symptomat
children
leukemia
hsct
higher
viral
load
bal
report
larg
prospect
studi
hsct
patient
kipyv
wupyv
show
cumul
incid
respect
year
season
pattern
increas
rate
patient
year
age
hazard
ratio
respect
sputum
product
wheez
associ
kipyv
wupyv
detect
graftvshost
diseas
cytomegaloviru
reactiv
neutropenia
lymphopenia
hospit
death
pend
studi
routin
test
kipyv
wupyv
recommend
current
data
support
treatment
kipyv
wupyv
lrtid
work
group
recogn
persontoperson
transmiss
carv
lead
measur
prevent
infect
control
measur
tabl
recommend
implement
level
patient
rel
healthcar
worker
insid
outsid
medic
institut
tabl
administr
ivig
prepar
hsct
leukemia
patient
hypogammaglobulinemia
gl
may
reduc
risk
morbid
mortal
secondari
carv
rtid
ciii
rsv
outbreak
commun
indic
increas
risk
exposur
use
intraven
monoclon
antibodi
specif
rsvf
protein
palivizumab
may
consid
pediatr
patient
age
year
monthli
prophylaxi
ciii
indic
patient
group
balanc
cost
clinic
benefit
screen
patient
carv
current
indic
unless
indic
context
infect
control
investig
nosocomi
transmiss
prevent
thu
laboratori
test
focu
symptomat
patient
tabl
take
account
clinic
impact
carv
hsct
leukemia
patient
differ
among
center
technic
financi
resourc
comprehens
carv
diagnost
multiplex
nat
work
group
recommend
priorit
laboratori
test
specif
carv
influenza
rsv
hpiv
tabl
reflect
clinic
impact
compar
carv
work
group
distinguish
need
treatment
influenza
b
rsv
hpiv
take
account
higher
risk
poor
outcom
specif
patient
group
treatment
rsv
hpiv
may
involv
deferr
condit
therapi
treatment
aerosol
ribavirin
offlabel
use
system
ribavirin
wherea
gener
recommend
carv
made
time
tabl
correspond
modal
rsv
therapi
system
ribavirin
summar
tabl
respect
work
group
cautiou
use
intraven
monoclon
antibodi
specif
rsvf
protein
exist
data
outsid
singl
case
report
support
benefici
effect
cost
high
therefor
young
age
year
allogen
hsct
patient
lrtid
high
risk
progress
rsv
lrtid
might
consid
treatment
intraven
monoclon
antibodi
specif
rsvf
protein
eg
palivizumab
mgkg
bodi
weight
ciii
supplementari
tabl
drug
consid
patient
group
withhold
treatment
rsv
infect
might
consid
select
stabl
leukemia
hsct
patient
care
evalu
risk
factor
morbid
mortal
possibl
appropri
followup
visit
consid
exampl
remiss
underli
diseas
absenc
immunosuppress
drug
treatment
absenc
risk
factor
associ
lrtid
mortal
ciii
although
center
would
treat
patient
hpiv
urtid
risk
factor
list
tabl
treatment
hpiv
urtid
gener
recommend
given
clinic
undefin
risk
benefit
ratio
ciii
overal
evid
limit
patient
autolog
hsct
andor
hematooncolog
diseas
infect
control
measur
appli
patient
undergo
autolog
hsct
chemotherapi
hematooncolog
diseas
carv
urtid
lrtid
biii
deferr
conditioningchemotherapi
consid
patient
carvrtid
schedul
autolog
hsct
chemotherapi
hematooncolog
diseas
biii
treatment
carv
rtid
influenza
gener
recommend
patient
undergo
autolog
hsct
chemotherapi
hematooncolog
diseas
ciii
work
group
acknowledg
despit
grow
awar
infect
carv
hsct
leukemia
patient
welldesign
studi
larg
lack
evalu
diagnost
therapeut
strategi
carv
diagnost
level
studi
need
identifi
appropri
diagnost
test
specimen
upper
lower
respiratori
tract
detect
carv
peripher
blood
associ
signific
lrtid
dissemin
diseas
poor
outcom
requir
evalu
specif
design
studi
interest
identifi
confirm
risk
factor
sever
diseas
poor
outcom
evalu
laboratori
marker
virusspecif
immun
surrog
marker
diseas
recoveri
recent
attempt
use
rsv
load
virolog
surrog
marker
antivir
treatment
small
interf
rna
andor
clinic
outcom
may
pacemak
role
carv
importantli
current
avail
treatment
carv
urtid
lrtid
lack
rigor
evalu
appropri
size
prospect
random
control
trial
need
compar
aerosol
ribavirin
system
oral
ribavirin
evalu
role
expens
ivig
prepar
combin
ribavirin
determin
use
intraven
monoclon
antibodi
specif
rsvf
protein
palivizumab
motavizumab
postexposur
prophylaxi
highrisk
patient
well
therapi
rsv
urtid
lrtid
develop
vaccin
seen
import
area
research
final
better
understand
indirect
alloimmun
patholog
carv
clinic
outcom
import
also
depend
better
definit
direct
viral
impact
